<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777424</url>
  </required_header>
  <id_info>
    <org_study_id>AGR_2014-22</org_study_id>
    <nct_id>NCT02777424</nct_id>
  </id_info>
  <brief_title>Prothrombin Complex Concentrate Versus Fresh Frozen Plasma to Correct Coagulation Disorders in Adult Neurosurgical Patients</brief_title>
  <acronym>CLOT-CRANE</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <brief_summary>
    <textblock>
      This prospective, randomized, multicenter study is performed to determine whether prothrombin
      complex concentrates confers any benefits over fresh frozen plasma in adult neurological
      patients with coagulation disorders (PT value less than 60%).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The coagulation disorders increase the risk of bleeding and are a risk factor of intracranial
      hemorrhagic complications in neurosurgical patients. They are diagnosed more often in
      emergency on a PT value less than 60% and so they should be corrected as soon as possible.
      Two therapeutic strategies are proposed by French or international recommendations:
      transfusion of fresh frozen plasma (FFP) or administration of prothrombin complex
      concentrates (PCC).

      This prospective, randomized, multicenter study with blinded assessment of the primary
      endpoint, is performed to determine whether PCC confers any benefits over FFP in the
      neurological patients with coagulation disorders.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with correction of prothrombin time (PT more than 60%)</measure>
    <time_frame>End of treatment administration (an average of 1 hour)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Intracranial Hemorrhages</condition>
  <arm_group>
    <arm_group_label>Prothrombin Complex Concentrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of a single dose of prothrombin complex concentrate (25 U/kg equivalent factor IX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fresh Frozen Plasma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of a single dose of fresh frozen plasma of 15 mL/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prothrombin Complex Concentrate</intervention_name>
    <description>Non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C &amp; S</description>
    <arm_group_label>Prothrombin Complex Concentrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fresh Frozen Plasma</intervention_name>
    <description>Pooled collection of plasma from donors</description>
    <arm_group_label>Fresh Frozen Plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with spontaneous intracranial hemorrhage or traumatic intracranial hemorrhage
             or patient requiring neurological surgery

          -  Coagulation disorder defined by PT less than 60%

        Exclusion Criteria:

          -  Concomitant use with oral anticoagulant drugs

          -  Acquired deficiency of coagulation factors whose treatment is established

          -  Hypersensitivity to a PCC

          -  History of thrombocytopenia induced by heparin

          -  Disseminated intravascular coagulation

          -  Extracranial active bleeding

          -  Hypersensitivity to vitamin K
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurence SALOMON</last_name>
    <email>lsalomon@for.paris</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benoit TAVERNIER</last_name>
      <email>Benoit.TAVERNIER@CHRU-LILLE.FR</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de NANCY</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard AUDIBERT, MD</last_name>
      <phone>0033383851403</phone>
      <email>g.audibert@chu-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondation Ophtalmologique Adolphe de Rothschild (FOR)</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence SALOMON, MD, PhD</last_name>
      <email>lsalomon@for.paris</email>
    </contact>
    <investigator>
      <last_name>Anne GODIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc fischler</last_name>
      <email>m.fischler@hopital-foch.org</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

